Evidence map›Paper›PMID 30832406›Full record

ArticleInternational journal of molecular sciences2019

The Risk of Recurrence of Subacute Thyroiditis Is HLA-Dependent.

Magdalena Stasiak, Bogusław Tymoniuk, Bartłomiej Stasiak, Andrzej Lewiński

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. How to manage subacute thyroiditis.Drugs in context · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Novel Insight into Non-Genetic Risk Factors of Graves' Orbitopathy.International journal of environmental research and public health · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Magdalena StasiakDepartment of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital - Research Institute, 93-338 Lodz, Poland. mstasiak33@gmail.com.ORCID 0000-0002-2910-7691
Bogusław TymoniukDepartment of Immunology, Rheumatology and Allergy, Medical University of Lodz, 92-213 Lodz, Poland. boguslaw.tymoniuk@umed.lodz.pl.
Bartłomiej StasiakInstitute of Information Technology, Lodz University of Technology, 90-924 Lodz, Poland. bartlomiej.stasiak@p.lodz.pl.
Andrzej LewińskiDepartment of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital - Research Institute, 93-338 Lodz, Poland. alewin@csk.umed.lodz.pl.ORCID 0000-0002-8748-3337
Medical University of Lodz · PLLodz University of Technology · PLPolish Mother’s Memorial Hospital Research Institute · PL

Funding

Statutory funds from the Polish Mother`s Memorial Hospital - Research Institute, Lodz, Poland, and from the Medical University of Lodz, Lodz, Poland 503/1-152-01/503-11-002
6 · The paper itself

Abstract

The frequency of recurrence of subacute thyroiditis (SAT) is rather high, reaching 20⁻30%. The reason for SAT relapse is still unknown. Recently, we have demonstrated the association between SAT and the presence of HLA-B*18:01, DRB1*01, and C*04:01, apart from the previously known HLA-B*35. The aim of the present study was to evaluate the correlation between SAT-associated HLA haplotypes and the risk of SAT recurrence. HLA-A, -B, -C, -DQB1 and -DRB1 were genotyped using a next-generation sequencing method in 49 SAT patients. The patients were divided into the following HLA groups: 1. HLA-B*35 and/or HLA-C*04, but without any other of the analyzed antigens; 2. HLA-DRB1*01, regardless of the co-presence of HLA-B*35 or -C*04:01, but without HLA-B*18:01; 3. HLA-B18 only, without any other antigen; 4. HLA-B*18:01 plus -B*35, regardless of the presence of any other analyzed antigens. The recurrence rate was compared between the groups. The recurrence rate was significantly increased in patients with HLA-B*18:01 plus HLA-B*35. In conclusion, the risk of SAT recurrence was HLA-dependent and the determining factor was the co-presence of HLA-B*18:01 and -B*35. In such high-risk patients, the steroid treatment regimen should be intensified with a slower dose reduction.

Indexed as

AdultBiomarkersFemaleHLA AntigensHumansMaleMiddle AgedRecurrenceThyroiditis, SubacuteBiomarkersHLA AntigensHLArecurrencerisk factorsteroid dosesubacute thyroiditis

Identifiers

PMID30832406
PMCPMC6429176
OpenAlexW2918178685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.